Expert Interview
Discussing Mirdametinib, an investigational MEK inhibitor, in neurofibromatosis type 1 (NF1), and how it compares to selumetinib
Ticker(s): SWTXInstitution: Mayo Clinic
- Consultant, Department of Medical Genetics & Director of NF1 clinic at Mayo.
- Research involves several collaborative basic research studies in the field of neurofibromatosis, in conjunction with Mayo's Neuro-Oncology Program and departments of Radiology and Neurologic Surgery.
- Holds a leadership role in collaborative studies looking at children, adolescents and young adults with neurofibromatosis 1 and progressive plexiform neurofibromas as well as adult patients with neurofibromatosis 1 and extensive plexiform and paraspinal neurofibromas.
Roughly how many patients with neurofibromatosis do you manage?
Added By: c_adminOn the Koselugo Label, the response rate is 66%, however under reins criteria it is 41%. Mirdametinib under BICR is 51%. What is the difference between Reins Criteria and BICR? Does Koselugo have a better responder rate of 66% or should you use the reins criteria of 41?
Added By: mathewWhy is Koselugo not approved for Adults? Do Adults need treatment? How do Plexiform present in Adults vs Pediatrics?
Added By: mathewHow significant is the food effect? I understand that Mirda does not require Fasting but Koselugo does require fasting? Is this a big differentiation feature? Do both still require twice a day dosing?
Added By: mathewDo you surgically resect after using a MEK inhibitor?
Added By: mathewWhat is the drop out rate that you have observed in the real world with Koselugo?
Added By: mathewIt appears that Mirda has a significantly higher grade 3 AE event vs Koselugo? Yet discontinuation is less, why?
Added By: mathewWould a once a day or less frequent dose be a value add to the field?
Added By: mathewAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
